What we do BIBCOL is a Central Public Sector Unit manufacturing Oral Polio Vaccine, Zinc Tablets, and other biological medicines, supporting national immunization and health programs in India. |
Founded in 1,989 |
Market share Key supplier of Oral Polio Vaccine to India's National Immunisation Programme with government backing. |
Problem solved Provides affordable vaccines and medicines to prevent and manage infectious diseases and malnutrition. |
Top clients or who we serve Primarily serves Indian government health programs (B2G), supporting national public health initiatives. |
Key management Dr. Sanjay Kumar Mishra (Managing Director since Sept 2021) |
Our journey and innovations Started OPV production in 1996; upgraded to WHO GMP in 2006; diversified into plasma medicines and Oral Cholera Vaccine recently. |
Where we operate India, primarily serving government health sector. |
Top products or what we offer Oral Polio Vaccine, Zinc Tablets, BIBSANIT kits, Plasma derived medicines, Oral Cholera Vaccine. |
Top brands Oral Polio Vaccine - primary product; Zinc Tablets - supplementary product; BIBSANIT - diarrhea management kit. |
Raw materials needed - |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue predominantly from government contracts which are recurring as part of health programs. |
Our industry position Strategic government vaccine supplier; faces challenges but is crucial for public health immunisation coverage. |
Financial highlights FY 2020-21 revenue Rs 85.33 crore, net loss Rs 4.75 crore; FY 2022-23 segment revenue Rs 44.61 crore with operational losses. |
Geographical revenue split Revenue mainly from Indian government contracts; domestic market focus. |
Order book - |
Whats driving growth Government immunisation programs, vaccine diversification, and new project development like Covaxin production. |
Our future plans Expanding into plasma-derived medicines and oral cholera vaccine production; potential Covaxin augmentation expected. |
Our green promise - |
Our people and values Focus on competency building and employee skill enhancement through training and teamwork. |
Key challenges ahead Financial losses, need for modernization, competition, and maintaining WHO compliance standards. |
Interesting facts First OPV production started in 1996; shifted to bivalent OPV in 2016 as per WHO guidelines. |
Risks and strategy Operational losses mitigated by diversifying product portfolio and aligning with government health priorities. |
